Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FY5RC
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,384
Award facts
- Contract value 100% obligated
- $13,384.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,384.49 to AmerSourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on January 27, 2026, with an ultimate completion date of January 28, 2026. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a task order under AmerSourceBergen's parent company, Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031, serving as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerSourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, supplies critical medications across multiple therapeutic domains to federal medical procurement needs, particularly for military and veteran healthcare systems. The DLA Troop Support Medical IDC encompasses an extensive range of medical commodities including specialty medications, brand-name and generic drugs, vaccines, and related medical supplies. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in treating inflammatory conditions, aligning with the company's portfolio of specialized pharmaceutical products delivered through the DLA supply chain to support federal healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FY5RC?
SPE2DR26FY5RC was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FY5RC worth?
The government has obligated $13,384 on SPE2DR26FY5RC.
Is contract SPE2DR26FY5RC an order under another contract?
Yes. SPE2DR26FY5RC is a delivery order under SPE2DR25D1006, an indefinite delivery contract.
Was contract SPE2DR26FY5RC competed?
The extent of competition for SPE2DR26FY5RC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award